| Vasculitis |
NCT05984251: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants |
|
|
| Completed | 1 | 48 | Europe | CCX168, Placebo | Amgen | Vasculitis, Systemic Lupus Erythematosus (SLE) | 09/10 | 04/11 | | |
NCT06004960: A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants |
|
|
| Completed | 1 | 6 | US | [14C]CCX168 | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 12/14 | 12/14 | | |
NCT05988021: A Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168 |
|
|
| Completed | 1 | 16 | US | CCX168 | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 02/16 | 05/16 | | |
NCT06004947: A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications |
|
|
| Completed | 1 | 32 | US | CCX168, Midazolam, Celecoxib, Itraconazole, Rifampicin | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 03/16 | 06/16 | | |
NCT05988008: A Study of CCX168 in Japanese and Caucasian Healthy Adult Males |
|
|
| Completed | 1 | 80 | Japan | CCX168, Avacopan, Placebo | Amgen | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis | 01/18 | 09/18 | | |
ChiCTR-IIC-15007622: An observational study to evaluate how to early diagnosis and treatment the patients with eosinophilic granulomatosis with polyangiitis |
|
|
| Not yet recruiting | 1 | 140 | | ICS ;oral glucocorticoid ;oral glucocorticoid and CTX ;oral glucocorticoid and CTX | The first affiliated hospital of Guangzhou Medical University; The first affiliated hospital of Guangzhou Medical University, Self-financing | EGPA | | | | |
NCT05353179: Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers |
|
|
| Not yet recruiting | 1 | 88 | RoW | Meperizumab injection, NUCALA® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Granulomatosis With Polyangiitis, Hemophagocytic Syndrome | 10/22 | 10/22 | | |
NCT05702983: The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects |
|
|
| Completed | 1 | 20 | US | STSA-1002 subcutaneous injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Antineutrophil Cytoplasmic Antibody Associated Vasculitis | 04/23 | 04/23 | | |
2023-000381-34: Study in healthy adults to explore a children's liquid formulation compared to Avacopan 10 mg capsule adult formulation |
|
|
| Not yet recruiting | 1 | 31 | US | Avacopan, CCX168, Capsule, Oral liquid | ChemoCentryx, ChemoCentryx | Anti-Neutrophil Cytoplasmic Antibody associated vasculitis, ANCA-associated vasculitis, Body processes [G] - Immune system processes [G12] | | | | |
NCT06316076: Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases |
|
|
| Recruiting | 1 | 48 | RoW | CD19-CAR-DNT cells, Cyclophosphamide, Fludarabine | RenJi Hospital, Guangdong Ruishun Biotech Co., Ltd | Systemic Lupus Erythematosus, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis | 06/24 | 06/26 | | |
NCT06285279: FKC288 in Participants With Autoimmune Kidney Diseases |
|
|
| Recruiting | 1 | 24 | RoW | FKC288 | Nanjing University School of Medicine | Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy - PLA2R Induced, IgG4-Related Diseases | 12/26 | 12/28 | | |
GLEAM, NCT06294236: Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases |
|
|
| Recruiting | 1 | 36 | US | SC291, Cyclophosphamide, Fludarabine | Sana Biotechnology | Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis | 12/27 | 03/28 | | |
IRIS-RD-01, NCT06581562: Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. |
|
|
| Recruiting | 1 | 30 | US | AB-101, ALLONK, RITUXIMAB, CYCLOPHOSPHAMIDE, FLUDARABINE, Rituximab, Cyclophosphamide, Fludarabine | IRIS Research and Development, LLC, Artiva Biotherapeutics, Inc. | Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus | 07/27 | 12/28 | | |
NCT06420154: The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 9 | RoW | anti-CD19-CAR-T cells | First Affiliated Hospital of Wenzhou Medical University, Shanghai First Song Therapeutics Co., Ltd | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome | 05/27 | 05/27 | | |
| Not yet recruiting | 1 | 24 | NA | KYV-101, Cyclophosphamide, Fludarabine | David Porter, Kyverna Therapeutics | Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis | 06/28 | 06/28 | | |
NCT06462144: IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy |
|
|
| Recruiting | 1 | 36 | RoW | IMPT-514 CART Cell Injection | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM) | 05/25 | 10/26 | | |
NCT06196905: An Exploratory Study of MT-2990 in Patients With AAV |
|
|
| Recruiting | 1 | 10 | Japan | MT-2990 | Mitsubishi Tanabe Pharma Corporation | Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV) | 08/25 | 08/25 | | |
NCT06548607: Clinical Study on Targeted CD19 CAR-T Therapy for Autoimmune Diseases |
|
|
| Recruiting | 1 | 20 | RoW | RD06-04 CART Cell Injection | Nanjing Bioheng Biotech Co., Ltd. | SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome, Autoimmune Diseases | 07/26 | 07/27 | | |
NCT06549296: Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 12 | RoW | RD06-04 CART Cell Injection | Nanjing Bioheng Biotech Co., Ltd. | Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome, Autoimmune Diseases | 08/26 | 08/27 | | |
NCT06548620: A Study of RD06-04 in Patients With Active Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 18 | RoW | RD06-04 cell infusion | Nanjing Bioheng Biotech Co., Ltd. | SLE (Systemic Lupus), Sclerosis, ANCA Associated Vasculitis, IIM, SS, MS, NMO Spectrum Disorder, MG | 08/26 | 08/27 | | |
NCT05263817: A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis |
|
|
| Recruiting | 1 | 75 | RoW | CD19/BCMA CAR T-cells, CD19/BCMA CAR T-cells injection | Zhejiang University, Yake Biotechnology Ltd. | POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, Vasculitis | 10/24 | 10/24 | | |
NCT06056921: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease |
|
|
| Recruiting | 1 | 24 | RoW | CD19 targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 12/25 | 08/26 | | |
